InvestorsHub Logo
Followers 32
Posts 5818
Boards Moderated 0
Alias Born 05/23/2006

Re: bfiest post# 311541

Tuesday, 09/12/2017 8:06:17 AM

Tuesday, September 12, 2017 8:06:17 AM

Post# of 346114
Just curious as to why no PR on the EMSO presentation Sept 9...

https://cslide.ctimeetingtech.com/library/esmo/browse/search/5uD#2Bb5o0JE

SK from the CC...

compelling but no pr.... and the right hands... we;ve been saying that for years.... so it's been in the wrong hands..

The subset analysis, which supports the combination of bavituximab with checkpoint inhibitors, is compelling but needs further clinical validation. This data, combined with findings from our collaborators at Memorial Sloan Kettering Cancer Center or MSKCC supporting combinations with cellular therapies including CAR-T and the ongoing trials from our partners at the National Comprehensive Cancer Network or NCCN, all as outlined in our earnings release, have bolstered our belief that our bavituximab program can be successfully advanced in the right hands.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News